About us
Subtractiv Therapeutx is a promising biopharma company in the immunotherapy space. We hold exclusive European and North American rights to a novel immunotherapy based on a breakthrough technology platform – Immunopheresis™, and has received initial European regulatory approval for commercialization.
Immunopheresis is designed to address unmet medical needs in cancer, inflammatory, cardiovascular, renal and autoimmune diseases and to be accessible to broad patient populations.
With a strong talent base and financial resources, Subtractiv Therapeutx is on an accelerated path to make its therapies widely available via partnerships with leading hospitals around the world.
Key facts
1
Subtractiv Therapeutx’s breakthrough blood-filtering immunotherapy device works external to the body and received FDA Breakthrough Device recognition in 2018
2
With an initial focus on immuno-oncology, Subtractiv Therapeutx has already secured CE Mark approval for use in adults with advanced, refractory, triple-negative breast cancer in Europe.
3
Subtractiv Therapeutx is working with it’s partner on the replicable Immunopheresis platform to create a robust pipeline of immunotherapy treatments.
4
With our partners we are working on significantly expanding approved indications in primary and metastatic solid tumors
Our Mission
To improve the quality of life for patients
in a meaningful way and expedite their
path to a healthy future.
VISION
Subtractiv Therapeutx reimagines healing
All to often, patients face the challenging decision of sacrificing their quality of life to obtain treatment for serious, life-threatening diseases. Often choosing not to participate in care at all. We believe people should not have to make trade-offs between living fulfilling lives and healing.
We envision a future where no one needs to sacrifice living their life to the fullest in order to receive life-saving treatment.